litlas
ログインアカウント作成

Stephan Stilgenbauer

1993–2026 年に発表

284
論文数
51,371
被引用数
120
h 指数
270
i10 指数

被引用数

Stephan Stilgenbauer の年別被引用数1976 年: 被引用 1 件1993 年: 被引用 1 件1994 年: 被引用 4 件1995 年: 被引用 6 件1996 年: 被引用 9 件1997 年: 被引用 30 件1998 年: 被引用 32 件1999 年: 被引用 76 件2000 年: 被引用 85 件2001 年: 被引用 102 件2002 年: 被引用 171 件2003 年: 被引用 158 件2004 年: 被引用 153 件2005 年: 被引用 197 件2006 年: 被引用 188 件2007 年: 被引用 186 件2008 年: 被引用 230 件2009 年: 被引用 203 件2010 年: 被引用 254 件2011 年: 被引用 255 件2012 年: 被引用 261 件2013 年: 被引用 237 件2014 年: 被引用 369 件2015 年: 被引用 452 件2016 年: 被引用 364 件2017 年: 被引用 466 件2018 年: 被引用 520 件2019 年: 被引用 1,456 件2020 年: 被引用 1,762 件2021 年: 被引用 1,664 件2022 年: 被引用 1,204 件2023 年: 被引用 925 件2024 年: 被引用 1,616 件2025 年: 被引用 707 件2026 年: 被引用 42 件1977〜1992 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,257 件、この内訳の 23.9%ドイツ: 引用元論文 1,267 件、この内訳の 9.3%イギリス: 引用元論文 1,005 件、この内訳の 7.4%中国: 引用元論文 994 件、この内訳の 7.3%イタリア: 引用元論文 889 件、この内訳の 6.5%フランス: 引用元論文 641 件、この内訳の 4.7%スペイン: 引用元論文 540 件、この内訳の 4%カナダ: 引用元論文 416 件、この内訳の 3.1%オランダ: 引用元論文 410 件、この内訳の 3%オーストラリア: 引用元論文 400 件、この内訳の 2.9%スイス: 引用元論文 369 件、この内訳の 2.7%スウェーデン: 引用元論文 292 件、この内訳の 2.1%
0%23.9%その他 23.1%

機関

分野

  • Medicine66.9%
  • Biochemistry, Genetics and Molecular Biology26.9%
  • Immunology and Microbiology3.5%
  • Neuroscience0.8%
  • Computer Science0.5%
  • Chemistry0.5%
  • その他0.9%

トピック

  • Chronic Lymphocytic Leukemia Research14.2%
  • Lymphoma Diagnosis and Treatment11.8%
  • Immunodeficiency and Autoimmune Disorders3.7%
  • CAR-T cell therapy research2.9%
  • Chronic Myeloid Leukemia Treatments2.1%
  • Viral-associated cancers and disorders1.9%
  • その他63.4%

共著者

全論文

検索で開く
  1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    著者: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps - Blood 2018 被引用: 1,689

  2. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

    著者: John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Mustafa Nuri Yenerel, Árpád Illés, Neil E. Kay, José A. García‐Marco, Anthony R. Mato, Javier Pinilla‐Ibarz, John F. Seymour, Stéphane Leprêtre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak - Journal of Clinical Oncology 2021 被引用: 635

  3. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

    著者: Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha‐Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michaël Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna‐Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens‐Martin Wendtner, Karl Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark‐David Levin, Marinus van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek - New England Journal of Medicine 2023 被引用: 291

  4. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

    著者: Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gülçin Özer, Marc Zapatka, Amy S. Ruppert, Ling Xue, Daniel Hsieh-Hsin Li, Susanne Steggerda, Matthias Versele, Sandeep S. Davé, Jenny Zhang, Ayse Selen Yilmaz, Samantha Jaglowski, Kristie A. Blum, Arletta Lozanski, Gerard Lozanski, Danelle F. James, Jacqueline C. Barrientos, Peter Lichter, Stephan Stilgenbauer, Joseph J. Buggy, Betty Chang, Amy J. Johnson, John C. Byrd - New England Journal of Medicine 2014 被引用: 1,254

  5. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    著者: Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, Anna‐Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova, A. M. Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Sebastian Böettcher, Eugen Tausch, Rod Humerickhouse, Barbara Eichhorst, Clemens‐Martin Wendtner, Anton W. Langerak, Karl-Anton Kreuzer, Matthias Ritgen, Valentin Goede, Stephan Stilgenbauer, Mehrdad Mobasher, Michael Hallek - New England Journal of Medicine 2019 被引用: 852

  6. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    著者: Michael Wang, Simon Rule, Peter Martin, André Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, W Wiktor-Jędrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate J. Newberry, Zhishuo Ou, Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Chang, Darrin M. Beaupre, Lori Kunkel, Kristie A. Blum - New England Journal of Medicine 2013 被引用: 1,687

  7. Mutations driving CLL and their evolution in progression and relapse

    著者: Dan A. Landau, Eugen Tausch, Amaro Taylor‐Weiner, Chip Stewart, Johannes G. Reiter, Jasmin Bahlo, Sandra Kluth, Ivana Božić, Mike Lawrence, Sebastian Böttcher, Scott L. Carter, Kristian Cibulskis, Daniel Mertens, Carrie Sougnez, Mara Rosenberg, Julian M. Hess, Jennifer Edelmann, Sabrina Kless, Michael Kneba, Matthias Ritgen, Anna Maria Fink, Kirsten Fischer, Stacey Gabriel, Eric S. Lander, Martin A. Nowak, Hartmut Döhner, Michael Hallek, Donna Neuberg, Gad Getz, Stephan Stilgenbauer, Catherine J. Wu - Nature 2015 被引用: 1,078

  8. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

    著者: Hartmut Döhner, Stephan Stilgenbauer, Axel Benner, Elke Leupolt, Alexander Kröber, Lars Bullinger, Konstanze Döhner, Martin Bentz, Peter Lichter - New England Journal of Medicine 2000 被引用: 3,296

  9. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    著者: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 被引用: 1,684

  10. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

    著者: Eugen Tausch, William Close, Anna Dolnik, Johannes Bloehdorn, Brenda Chyla, Lars Bullinger, Hartmut Döhner, Daniel Mertens, Stephan Stilgenbauer - Haematologica 2019 被引用: 203

  11. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

    著者: Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens‐Martin Wendtner, Tatiana Chagorova, Javier de la Serna, Marie‐Sarah Dilhuydy, Thomas Illmer, Stephen Opat, Carolyn Owen, Olga Samoylova, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Hartmut Döhner, Anton W. Langerak, Matthias Ritgen, Michael Kneba, Elina Asikanius, Kathryn Humphrey, Michael Wenger, Michael Hallek - New England Journal of Medicine 2014 被引用: 1,500

  12. Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity

    著者: Bola S. Hanna, Laura Llaó Cid, Murat Iskar, Philipp M. Roessner, Lara C. Klett, John Wong, Yashna Paul, Nikolaos Ioannou, Selcen Öztürk, Norman Mack, Verena Kalter, Dolors Colomer, Elı́as Campo, Johannes Bloehdorn, Stephan Stilgenbauer, Sascha Dietrich, Manfred Schmidt, Richard Gabriel, Karsten Rippe, Markus Feuerer, Alan G. Ramsay, Peter Lichter, Marc Zapatka, Martina Seiffert - Immunity 2021 被引用: 130

  13. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    著者: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutré, John F. Seymour, Talha Munir, Soham D. Puvvada, Clemens‐Martin Wendtner, Andrew W. Roberts, Wojciech Jurczak, Stephen P. Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari H. Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G. Wierda - The Lancet Oncology 2016 被引用: 796

  14. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

    著者: John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan‐Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony R. Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach - Blood 2023 被引用: 119

  15. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

    著者: Othman Al‐Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna‐Maria Fink, Sandra Robrecht, Olga Samoylova, Anna Marina Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Eugen Tausch, William Schary, Matthias Ritgen, Clemens‐Martin Wendtner, Karl-Anton Kreuzer, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek, Kirsten Fischer - The Lancet Oncology 2020 被引用: 327

  16. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    著者: Othman Al‐Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer - Nature Communications 2023 被引用: 93

  17. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

    著者: Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Étienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott D. Lunin, F. Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P Skarbnik, Amanda F. Cashen, David T. Weaver, Virginia Kelly, Barry Turnbull, Stephan Stilgenbauer - Blood 2018 被引用: 341

  18. Tumor-derived exosomes modulate PD-L1 expression in monocytes

    著者: Franziska Haderk, Ralph Schulz, Murat Iskar, Laura Llaó Cid, Thomas Stefan Worst, Karolin V. Willmund, Angela Schulz, Uwe Warnken, Jana Seiler, Axel Benner, Michelle Neßling, Thorsten Zenz, Maria Göbel, Jan Dürig, Sven Diederichs, Jérôme Paggetti, Etienne Moussay, Stephan Stilgenbauer, Marc Zapatka, Peter Lichter, Martina Seiffert - Science Immunology 2017 被引用: 292

  19. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

    著者: Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Valter Torri, Christopher P. Fox, Paul La Rosée, Elisabeth Schorb, Achille Ambrosetti, Alexander Röth, Claire Hemmaway, Angela Ferrari, Kim Linton, Roberta Rudà, Mascha Binder, Tobias Pukrop, Monica Balzarotti, Alberto Fabbri, Peter Johnson, Jette Sønderskov Gørløv, Georg Heß, Jens Panse, Francesco Pisani, Alessandra Tucci, Stephan Stilgenbauer, Bernd Hertenstein, Ulrich Keller, Stefan W. Krause, Alessandro Levis, Hans‐Joachim Schmoll, Franco Cavalli, Jürgen Finke, Michele Reni, Emanuele Zucca, Gerald Illerhaus - The Lancet Haematology 2016 被引用: 599

  20. Molecular map of chronic lymphocytic leukemia and its impact on outcome

    著者: Binyamin A. Knisbacher, Ziao Lin, Cynthia K. Hahn, Ferran Nadeu, Martí Duran‐Ferrer, Kristen E. Stevenson, Eugen Tausch, Julio Delgado, Alex Barbera-Mourelle, Amaro Taylor‐Weiner, Pablo Bousquets‐Muñoz, Ander Díaz‐Navarro, Andrew Dunford, Shankara Anand, Helene Kretzmer, Jesús Gutiérrez‐Abril, Sara López-Tamargo, Stacey M. Fernandes, Clare Sun, Mariela Sivina, Laura Z. Rassenti, Christof Schneider, Shuqiang Li, Laxmi Parida, Alexander Meissner, François Aguet, Jan A. Burger, Adrian Wiestner, Thomas J. Kipps, Jennifer R. Brown, Michael Hallek, Chip Stewart, Donna Neuberg, José I. Martín‐Subero, Xosé S. Puente, Stephan Stilgenbauer, Catherine J. Wu, Elı́as Campo, Gad Getz - Nature Genetics 2022 被引用: 148

  21. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

    著者: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F. Seymour, Steven Coutré, Wojciech Jurczak, Stephen P. Mulligan, Anna Schuh, Sarit Assouline, Clemens‐Martin Wendtner, Andrew W. Roberts, Matthew S. Davids, Johannes Bloehdorn, Talha Munir, Sebastian Böttcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer A. Arzt, Su Young Kim, Maria Verdugo, Gary Gordon, Michael Hallek, William G. Wierda - Journal of Clinical Oncology 2018 被引用: 313

  22. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

    著者: Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, Christopher P. Fox, Elisabeth Schorb, Claudia Celico, Monica Falautano, Alessandro Nonis, Paul La Rosée, Mascha Binder, Alberto Fabbri, Fiorella Ilariucci, Mauro Krampera, Alexander Röth, Claire Hemmaway, Peter Johnson, Kim Linton, Tobias Pukrop, Jettes Sønderskov Gørløv, Monica Balzarotti, Georg Heß, Ulrich Keller, Stephan Stilgenbauer, Jense Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Manuela Zanni, Stefan W. Krause, Hans‐Joachim Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Lorenz Thurner, Giuseppina Cabras, Elsa Pennese, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jürgen Finke, Antonella Ferranti, Kelly Cozens, Elvira Burger, Nicoletta Ielmini, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, IELSG32 study investigators - Leukemia 2022 被引用: 162

  23. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

    著者: Othman Al‐Sawaf, Can Zhang, Tong Lu, Michael Z. Liao, Anesh Panchal, Sandra Robrecht, Travers Ching, Maneesh Tandon, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Sebastian Böttcher, Karl‐Anton Kreuzer, Brenda Chyla, Dale Miles, Clemens‐Martin Wendtner, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer - Journal of Clinical Oncology 2021 被引用: 142

  24. The genomic and transcriptional landscape of primary central nervous system lymphoma

    著者: Josefine Radke, Naveed Ishaque, Randi Koll, Zuguang Gu, Elisa Schumann, Lina Sieverling, Sebastian Uhrig, Daniel Hübschmann, Umut H. Toprak, Cristina López, Xavier Pastor Hostench, Simone Borgoni, Dilafruz Juraeva, Fabienne Pritsch, Nagarajan Paramasivam, Gnana Prakash Balasubramanian, Matthias Schlesner, Shashwat Sahay, Marc A. Weniger, Debora Pehl, Helena Radbruch, Anja Osterloh, Agnieszka Korfel, Martin Misch, Julia Onken, Katharina Faust, Peter Vajkoczy, Dag Moskopp, Yawen Wang, Andreas Jödicke, Lorenz Trümper, Ioannis Anagnostopoulos, Dido Lenze, Ralf Küppers, Michael Hummel, Clemens A. Schmitt, Otmar D. Wiestler, Stephan Wolf, Andreas Unterberg, Roland Eils, Christel Herold‐Mende, Benedikt Brors, Coordination (C1), Reiner Siebert, Susanne Wagner, Andrea Haake, Julia Richter, Gesine Richter, Roland Eils, Chris Lawerenz, Jürgen Eils, Jules N. A. Kerssemakers, Christina Jaeger-Schmidt, Ingrid Scholz, Anke Bergmann, Christoph Borst, Friederike Braulke, Birgit Burkhardt, Alexander Claviez, Martin Dreyling, Sonja Eberth, Hermann Einsele, Norbert Frickhofen, Siegfried Haas, Martin‐Leo Hansmann, Dennis Karsch, Nicole Klepl, Michael Kneba, Jasmin Lisfeld, Luisa Mantovani‐Löffler, Marius Rohde, German Ott, Christina Stadler, Peter Staib, Stephan Stilgenbauer, Thorsten Zenz, Normal Cells (WPN), Martin‐Leo Hansmann, Dieter Kube, Pathology and Analyte Preparation (WP2-3), Siegfried Haas, Wolfgang Hiddemann, Ulrike Kostezka, Peter Möller, Andreas Rosenwald, German Ott, Monika Szczepanowski, Sequencing and genomics (WP4-7), Ole Ammerpohl, Sietse Aukema, Vera Binder, Arndt Borkhardt, Andrea Haake, Jessica I. Hoell, Ellen Leich, Peter Lichter, Cristina López, Inga Nagel, Jordan Pischimariov, Bernhard Radlwimmer ほか 27 名 - Nature Communications 2022 被引用: 140